A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
Фаза 1
Завершено
NCT06262477
| Заболевание | Healthy Volunteer |
|---|
| Фаза | Фаза 1 |
|---|
| Спонсор | Biogen |
|---|
| Статус | Завершено |
|---|
| Участники | 300 участн. |
|---|
| Вмешательство | BIIB800, Actemra |
|---|
| Дата начала | 2.01.2024 |
|---|
| Дата завершения | 25.09.2024 |
|---|
| Публикация результатов | 6.10.2025 |
|---|
Кратко
The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.
Maximum Observed Serum Concentration (Cmax) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · micrograms per milliter (μg/mL)
| BIIB800 | 10.5 ± 43.3 micrograms per milliter (μg/mL) |
|---|
| Actemra | 10.0 ± 41.3 micrograms per milliter (μg/mL) |
|---|
| Ratio of GLSM | 1.05 (95% CI 0.974–1.13) |
|---|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · hours (h)*μg/ mL
| BIIB800 | 2380 ± 44.9 hours (h)*μg/ mL |
|---|
| Actemra | 2240 ± 41.1 hours (h)*μg/ mL |
|---|
| Ratio of GLSM | 1.07 (95% CI 0.988–1.15) |
|---|
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · h*μg/ mL
| BIIB800 | 2120 ± 45.9 h*μg/ mL |
|---|
| Actemra | 2000 ± 44.0 h*μg/ mL |
|---|
| Ratio of GLSM | 1.06 (95% CI 0.985–1.15) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.